S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Celgene Corporation to Present at Investor Conferences in September|
|Retrospective Analysis of Overall Survival Adjusting for Patient Crossover in Phase III Study of POMALYST®/IMNOVID® (Pomalidomide) in Previously Treated Multiple Myeloma Presented at EHA|
|Results from Phase III Study (AML-001) of VIDAZA® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at EHA|
|Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen|
|Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine|
|Celgene Reports Second Quarter 2014 Operating and Financial Results|
|Celgene Stockholders Approve Two-for-One Stock Split|
|Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis|
|Celgene Corporation to Announce Second Quarter 2014 Results on July 24, 2014|
|VentiRx Pharmaceuticals Provides Corporate and Clinical Update (2014/9/2)|
Click above to view more mutual fund data and stats for celg - Celgene Corp.